Form 4: Masimo Corp Director Craig B Reynolds Executes Stock Option and Sells Shares

Director Craig B Reynolds of Masimo Corp exercised stock options and sold 40,000 shares of common stock on April 26, 2024, according to a Form 4 filing with the SEC.

Summary

• Craig B Reynolds, a director at Masimo Corp, executed a non-qualified stock option to purchase 40,000 shares of common stock at a price of $23.04 on April 26, 2024.
• Simultaneously, Reynolds sold 40,000 shares of common stock at a weighted average price of $136.1654, with prices ranging from $135.46 to $137.81.
• Following these transactions, Reynolds directly owns 7,406 shares of Masimo Corp common stock.
• The transactions were executed pursuant to a Rule 10b5-1 sales plan adopted on May 17, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. It doesn't convey any explicit positive or negative information about the company's performance or outlook.

Industry Context

This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a broader trend within the medical technology industry. However, monitoring insider activity can provide insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Comparing Reynolds' transactions to those of other directors in similar medical technology companies would provide a better understanding of whether this activity is typical.
• For example, reviewing Form 4 filings of directors at companies like Medtronic or Stryker could offer a benchmark for assessing the magnitude and frequency of insider transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales mitigates any significant concerns.
• The impact on employees, customers, suppliers, and creditors is likely negligible.

Key Dates